In a study highlighted in Nature Metabolism, researchers led by Zhu and colleagues have identified a direct biochemical mechanism connecting cancer cell metabolism to the fidelity of cell division. The investigation demonstrates that lactate, a prominent metabolic byproduct of aerobic glycolysis, promotes faithful mitotic progression in tumour cells through a post-translational modification known as protein lactylation. Tumour cells characteristically rely on aerobic glycolysis—a metabolic phenomenon known as the Warburg effect—to sustain rapid cellular proliferation even in the presence of oxygen. While glycolysis has long been recognized for producing biosynthetic intermediates and regenerating NAD+ to sustain glycolytic flux, whether its metabolic byproducts act as direct signalling cues to stimulate cell division has remained an outstanding biological question.
To explore how glucose utilization intersects with the cell cycle, the investigators examined hepatocellular carcinoma, a primary liver cancer. Analysis revealed that the expression of the primary glucose transporter GLUT1 positively correlates with the expression of key mitotic genes in hepatocellular carcinoma tissues. Turning to hepatocellular carcinoma cell line models to probe the functional basis of this relationship, the authors found that subjecting cells to glucose deprivation severely disrupted normal mitotic progression. The deprivation of glucose led to measurable mitotic defects, including a significant reduction in histone H3 phosphorylation at serine 10, a marked increase in lagging chromosomes and chromatin bridges during cell division, enhanced micronucleus formation, and the abnormal activation of the cGAS–STING innate immune sensing pathway.
Crucially, experimental supplementation with lactate largely reversed these mitotic abnormalities in glucose-starved cancer cells, indicating that lactate itself, rather than downstream energy generation alone, serves as the critical functional agent. The findings pointed to an uncharacterized metabolic circuit whereby high glycolytic flux directly dictates the functional activation state of this central mitotic regulator.
To uncover the precise molecular mechanism by which glucose metabolism influences Aurora B, the authors combined co-immunoprecipitation assays with mass spectrometry. This systematic screening identified the glycolytic enzyme phosphoglycerate kinase 1, or PGK1, as a physical binding partner of Aurora B specifically under conditions of high glucose availability. Its physical association with a nuclear mitotic kinase under high-nutrient conditions suggested a direct coupling between the glycolytic machinery and chromosome segregation.
The team subsequently demonstrated that elevated concentrations of glucose and lactate stimulate the lactylation of PGK1 at lysine residue 131. This post-translational modification is catalysed by the histone acetyltransferase KAT2A, which utilizes the lactate generated by enhanced glycolytic flux to attach a lactyl moiety to the specific lysine residue. To confirm the necessity of this modification, the researchers generated a K131R point mutant that renders PGK1 incapable of undergoing lactylation at that site. Furthermore, using a genetic code expansion strategy that enables site-specific incorporation of lactyllysine into the protein, the authors verified that lactylation at lysine 131 markedly enhances the binding affinity between PGK1 and Aurora B.
Beyond serving as a scaffold, PGK1 was unexpectedly found to possess non-canonical protein kinase activity that directly modifies Aurora B. In vitro kinase assays revealed that upon binding Aurora B, K131-lactylated PGK1 acts as a protein kinase that phosphorylates Aurora B directly at threonine 232. Structural insights obtained through molecular docking and AlphaFold predictive modelling revealed that threonine 232 of Aurora B is optimally positioned within the catalytic cleft of lactylated PGK1. This alignment places the threonine hydroxyl group in close proximity to the gamma-phosphate of ATP, thereby facilitating direct phosphate transfer and enzymatic activation of Aurora B.
Once activated by PGK1-mediated phosphorylation, Aurora B initiates a phosphorylation cascade on downstream substrates that promotes tumour progression through both cell-autonomous and non-cell-autonomous mechanisms. Activated Aurora B directly phosphorylates histone H3 at serine 10, ensuring accurate chromosome alignment and faithful mitotic segregation to prevent catastrophic chromosome missegregation. Simultaneously, Aurora B phosphorylates cGAS, thereby suppressing the cGAS–STING-mediated innate immune response that would otherwise be triggered by cytoplasmic micronuclei and aberrant chromatin fragments. In contrast, under low-glucose conditions, the absence of PGK1 lactylation disrupts this complex, causing chromosome segregation failure, micronucleus formation, cGAS-STING activation, increased infiltration of cytotoxic CD8+ T cells, and suppression of tumour growth.
The identification of the PGK1–Aurora B activation axis addresses a major clinical dilemma in oncology. Although Aurora B has long been considered an attractive therapeutic target, the clinical development of direct Aurora B kinase inhibitors has been thwarted by severe on-target toxicities in normal proliferating tissues, most notably dose-limiting myelosuppression, leaving no approved Aurora B inhibitors available for clinical use. To circumvent this limitation, Zhu and colleagues engineered an interference peptide specifically designed to disrupt the physical interaction between PGK1 and Aurora B without directly inhibiting Aurora B’s intrinsic catalytic domain.
A key finding supporting this therapeutic strategy is the differential dependence of normal and malignant tissues on the PGK1–Aurora B axis. The authors demonstrated that PGK1 contributes only minimally to Aurora B phosphorylation in normal hepatocytes, whereas the pathway is heavily engaged in hepatocellular carcinoma cells due to their elevated glycolytic state. In preclinical mouse models of hepatocellular carcinoma, administration of the disruption peptide effectively suppressed tumour growth while largely sparing normal tissues. This selective vulnerability underscores the therapeutic potential of targeting non-canonical signalling axes specifically co-opted by cancer cells, offering a path to treat tumours while avoiding the debilitating toxicities of global kinase inhibition.
Despite these encouraging preclinical results, critical questions regarding physiological safety remain to be resolved. Commentators Jiuzuo Sun and Di Zhang note that the physiological role of the PGK1–Aurora B axis in other normal rapidly dividing tissues with high glycolytic activity—such as haematopoietic stem cells and hair follicle stem cells—has not yet been determined. Because myelosuppression is the principal dose-limiting toxicity that derailed earlier Aurora B inhibitors, rigorously defining the activity of this lactylation-dependent pathway in haematopoietic lineages will be essential to establish a genuine therapeutic window and assess long-term safety before any clinical translation can proceed.
More broadly, the study reinforces two emerging paradigms in modern cell biology. First, cellular metabolism operates not merely as an engine supplying energy and chemical building blocks, but as an active information-processing network wherein metabolic intermediates such as lactate function as bona fide signalling molecules that govern complex cellular behaviours. Second, metabolic enzymes frequently exhibit non-canonical, or moonlighting, functions that extend far beyond intermediary metabolism, as demonstrated by the protein kinase activity of PGK1. Whether other metabolic enzymes similarly translate nutritional and metabolic fluctuations into regulatory phosphorylation events represents an important frontier for understanding cellular homeostasis and discovering metabolic vulnerabilities in cancer.
Beyond its established role in promoting tumor cell proliferation, protein lactylation has been implicated across a wide range of physiological and pathological processes, including tumor metastasis and resistance to both chemotherapy and radiotherapy. The observation that lactate promotes faithful mitosis by coupling glycolytic activity directly to Aurora B activation reinforces an emerging regulatory paradigm in biology. Rather than functioning solely as an end product of glycolysis or a simple source of energy and biosynthetic precursors, lactate acts as an active signaling molecule that coordinates cellular behavior. This lactate-driven mechanism demonstrates how metabolic intermediates can operate within an information-processing network that senses nutrient states and directly regulates fundamental cellular events.
The structural and biochemical details of this axis highlight how metabolic changes directly control enzymatic activity and downstream immune signaling. Under high-glucose conditions, the histone acetyltransferase KAT2A utilizes abundant glycolytic lactate to catalyze the lactylation of PGK1 at lysine 131, markedly enhancing its binding affinity for Aurora B. Molecular docking and AlphaFold modeling showed that threonine 232 of Aurora B is positioned within the catalytic pocket of K131-lactylated PGK1, placing its hydroxyl group adjacent to the gamma-phosphate of ATP to enable direct phosphate transfer. Once activated, Aurora B phosphorylates histone H3 at serine 10 and cGAS, simultaneously ensuring accurate chromosome segregation and suppressing cGAS-mediated innate immune signaling. Conversely, low-glucose conditions disrupt this interaction, causing mitotic defects, including chromosomal lagging, chromatin bridges, and micronucleus formation, while triggering cGAS–STING activation alongside increased CD8+ T cell infiltration to suppress tumor growth.
These mechanistic insights offer a targeted strategy to overcome the persistent challenges associated with direct Aurora B inhibitors, which have suffered from dose-limiting myelosuppression and lack clinical approval. Because PGK1 contributes only minimally to Aurora B phosphorylation in normal hepatocytes but is prominently engaged in hepatocellular carcinoma cells, disrupting this specific interaction with an engineered peptide inhibited tumor growth in mouse models while largely sparing normal cells. Nevertheless, critical safety questions must still be resolved. Future investigations must evaluate the physiological significance of the PGK1–Aurora B axis in other normal, rapidly proliferating tissues that exhibit high glycolytic activity, such as hematopoietic stem cells and hair follicle stem cells. Clarifying the contribution of this pathway in these tissues will be vital for defining the therapeutic window, assessing long-term safety, and exploring whether other moonlighting metabolic enzymes present similar therapeutic vulnerabilities.
Subject of Research: Lactate-driven protein lactylation regulating mitotic fidelity and immune evasion in hepatocellular carcinoma
Article Title: Lactylation: a metabolic sensor for faithful mitosis
Article References: Sun, J., & Zhang, D. (2026). Lactylation: a metabolic sensor for faithful mitosis. Nature Metabolism, 8(11), 2216-2217. https://doi.org/10.1038/s42255-026-01649-y
Image Credits: AI Generated
DOI: 10.1038/s42255-026-01649-y
Keywords: lactylation, Aurora kinase B, phosphoglycerate kinase 1, hepatocellular carcinoma, mitosis, Warburg effect, cGAS-STING pathway, KAT2A, histone H3 phosphorylation, chromosome segregation, GLUT1, CD8+ T cells, moonlighting enzymes, protein kinase activity, peptide inhibitor, aerobic glycolysis

